ALISO VIEJO, Calif., May 15, 2013 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO) today announced that it has received four additional patents for its PEER Interactive technology. Two of the patents -- one in the US and one in Japan -- relate to the Company's method of classifying individual patients based on their unique Quantitative EEG (QEEG) responsivity profile. The third patent, issuing in Canada, relates to the Company's method of determining medication efficacy by comparing QEEG data measured before and after medication administration. The fourth patent, issuing in Japan, relates to the Company's method of recommending therapy based upon an individual's unique QEEG responsivity profile.
PEER Interactive correlates a reliable, well-normed neurophysiology test (QEEG) with a published physician outcome registry (PEER). A growing body of evidence -- 75 studies on PEERDossier.com -- have demonstrated reduced trial and error prescribing for physicians using QEEG. PEER studies have shown health outcomes that are two times better than treatment as usual.
Mental health is an area where treatments fail frequently due to the lack of objective, physiological tests to help physicians individualize prescriptions for their patients. In fact, the National Institute of Mental Health (NIMH) recently announced that it will drop the Diagnostic and Statistical Manual (the "DSM"), which is considered "the bible of Psychiatry", because of its poor correlation with treatment outcomes and its lack of scientific validity. According to Tom Insel, MD, Director of NIMH: "The weakness is its lack of validity. Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure."
CNS Response CEO George Carpenter commented, "In light of the need for objective, physiological measures to guide mental health treatment, and our current work with the US military, we will continue to develop, refine and protect our PEER platform."
About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years, and use of medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. The company's Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 35,000 outcomes for 8,700 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Investor Relations: Marty Tullio, Managing Partner McCloud Communications, LLC 949.553.9748 email@example.comSource:CNS Response